ABBV
TEM
Genetic data, but make it messy
Tempus AI is now dealing with a lawsuit that says the company crossed the line on genetic privacy. According to the complaint, it allegedly forced an acquired genetic testing business to hand over patient genetic data, then passed that information along to pharma partners including Eli Lilly and AbbVie.
Why this matters
This isn’t just a boring court filing tucked in a drawer somewhere. Genetic data is the kind of stuff regulators and consumers treat like the crown jewels. If the allegations stick, Tempus could face:
- legal expenses and settlement risk
- possible scrutiny under Illinois’ genetic privacy law
- a hit to trust with patients and healthcare partners
The bigger investor angle
Tempus has been trying to sell itself as an AI-powered healthcare growth story. But privacy lawsuits are the sort of thing that can turn a shiny narrative into a compliance slog. Even if the company fights the case, the headline alone is enough to remind investors that data-heavy healthcare companies live one lawsuit away from a very un-fun Monday.
Big picture: when your business is built on sensitive data, privacy issues don’t just land in legal — they can spill straight into the stock story.